研究者業績
  1. 研究者検索結果一覧
  2. 嘉田 晃子

嘉田 晃子

Akiko Kada

基本情報

所属
藤田医科大学 橋渡し研究シーズ探索センター  准教授
学位
社会健康医学 修士(2002年3月 京都大学)
J-GLOBAL ID
201801012345530637
researchmap会員ID
B000306689

研究キーワード

 2

研究分野

 2

論文

 113
  • Hideo Saka, Masahide Oki, Yoshikane Yamauchi, Chiyoe Kitagawa, Akiko Kada, Akiko M Saito, Haruhiko Kondo, Hirotaka Kida, Noriaki Takahashi, Akihiro Bessho, Katsuhiro Okuda, Hideki Miyazawa
    Respiratory investigation 62(2) 277-283 2024年3月  
    BACKGROUND: Secondary pneumothorax, which occurs most commonly in the elderly, is caused by underlying diseases. Cardiac dysfunction and other organ inefficiencies may render surgical repair impossible. Such non-operative and poor-risk cases are targets for pleurodesis, which involves the instillation of chemicals or irritants to the thoracic cavity through injection, bronchoscopic bronchial occlusion, or other procedures. Sterile graded talc has been used for pleurodesis mainly in Europe and the United States; however, only a few studies and case series investigating this topic have been published. This study evaluates the efficacy and safety of talc slurry pleurodesis. METHODS: Patients with inoperable secondary intractable pneumothorax, who were not candidates for surgical repair, were recruited. Four grams of sterilized talc was suspended in 50 mL of physiological saline and injected through a tube into the pleural cavity. Additional 50 mL of saline was subsequently injected through the same channel to clean the residual saline in the injection tube. Another additional talc instillation was allowed to control persistent air leakage. The primary endpoint was the proportion of drainage tube removal within 30 days after talc pleurodesis. RESULTS: Thirty-one patients were included in this study. In 23 out of 28 patients, the drainage tube could be removed within 30 days of talc instillation (82.1 %, 95 % CI = 63.1-93.9), exceeding the threshold of 36.0 % (p < 0.0001). The most common event was pain (11/28 patients, 39.3 %). CONCLUSIONS: Talc slurry pleurodesis is effective for intractable secondary pneumothorax, with minor side effects.
  • Tetsuya Mori, Tomoo Osumi, Akiko Kada, Kentaro Ohki, Yuhki Koga, Reiji Fukano, Naoto Fujita, Tetsuo Mitsui, Takeshi Mori, Akiko M Saito, Atsuko Nakazawa, Ryoji Kobayashi, Masahiro Sekimizu
    European journal of haematology 2023年12月19日  
    BACKGROUND: The benefit of adding rituximab to standard lymphomes malins B (LMB) chemotherapy for children with high-risk mature B-cell non-Hodgkin lymphoma (B-NHL) has previously been demonstrated in an international randomized phase III trial, to which the Japanese Pediatric Leukemia/Lymphoma Study Group could not participate. METHODS: To evaluate the efficacy and safety of rituximab in combination with LMB chemotherapy in Japanese patients, we conducted a single-arm multicenter trial. RESULTS: In this study, 45 patients were enrolled between April 2016 and September 2018. A total of 33 (73.3%), 5 (11.1%), and 6 (13.3%) patients had Burkitt lymphoma/leukemia, diffuse large B-cell lymphoma, and aggressive mature B-NHL, not otherwise specified, respectively. Ten (22.2%) and 21 (46.7%) patients had central nervous system disease and leukemic disease, respectively. The median follow-up period was 47.5 months. Three-year event-free survival and overall survival were 97.7% (95% confidence interval, 84.9-99.7) and 100%, respectively. The only event was relapse, which occurred in a patient with diffuse large B-cell lymphoma. Seven patients (15.6%) developed Grade 4 or higher non-hematologic adverse events. Febrile neutropenia was the most frequent Grade 3 or higher adverse event after the pre-phase treatment, with a frequency of 54.5%. CONCLUSION: The efficacy and safety of rituximab in combination with LMB chemotherapy in children with high-risk mature B-NHL was observed in Japan.
  • Yoshihito Kogure, Akiko Kada, Hiroya Hashimoto, Shinji Atagi, Yuichi Takiguchi, Hideo Saka, Noriyuki Ebi, Akira Inoue, Takayasu Kurata, Yuka Fujita, Yoichi Nishii, Hidetoshi Itani, Takeo Endo, Akiko M Saito, Takuo Shibayama, Nobuyuki Yamamoto, Akihiko Gemma
    JTO clinical and research reports 4(6) 100514-100514 2023年6月  
    INTRODUCTION: In the CAPITAL study, a randomized phase 3 study, wherein carboplatin plus nab-paclitaxel treatment was compared with docetaxel treatment for older patients with squamous-cell lung cancer, the former became the new standard of care for such patients. Our study aimed to evaluate whether the efficacy of second-line immune checkpoint inhibitors (ICIs) affected the primary analysis of overall survival (OS). METHODS: Herein, we performed a post hoc analysis of the impact of second-line ICIs on OS, safety in each group of participants aged more than 75 years, and intracycle nab-paclitaxel skip status. RESULTS: Patients were randomly allocated to the carboplatin plus nab-paclitaxel (nab-PC) arm (n = 95) or the docetaxel (D) arm (n = 95). Of these patients, 74 of 190 (38.9%) were transferred to ICIs for second-line treatment (nab-PC arm: 36, D arm: 38). A survival benefit was numerically observed only for patients for whom first-line therapy was terminated owing to disease progression (median OS [nab-PC arm]: with and without ICIs, 321 and 142 d, respectively; median OS [D arm]: with and without ICIs, 311 and 256 d, respectively). The OS among patients who received ICI after adverse events was similar in the two arms. In the D arm, a significantly higher frequency of grade greater than or equal to 3 adverse events was observed among patients aged more than or equal to 75 years (86.2%) than among those aged less than 75 years (65.6%, p = 0.041), including a significantly higher frequency of neutropenia (84.6% versus 62.5%, p = 0.032); no such differences were observed in the nab-PC arm. CONCLUSIONS: We found that second-line ICI treatment seemed to have a little impact on OS.
  • Ryota Kurogi, Akiko Kada, Kuniaki Ogasawara, Kunihiro Nishimura, Takanari Kitazono, Toru Iwama, Yuji Matsumaru, Nobuyuki Sakai, Yoshiaki Shiokawa, Shigeru Miyachi, Satoshi Kuroda, Hiroaki Shimizu, Shinichi Yoshimura, Toshiaki Osato, Nobutaka Horie, Izumi Nagata, Kazuhiko Nozaki, Isao Date, Yoichiro Hashimoto, Haruhiko Hoshino, Hiroyuki Nakase, Hiroharu Kataoka, Tsuyoshi Ohta, Hitoshi Fukuda, Nanako Tamiya, AI Kurogi, Nice Ren, Ataru Nishimura, Koichi Arimura, Takafumi Shimogawa, Koji Yoshimoto, Daisuke Onozuka, Soshiro Ogata, Akihito Hagihara, Nobuhito Saito, Hajime Arai, Susumu Miyamoto, Teiji Tominaga, Koji Iihara
    BMJ Open 13(4) e068642-e068642 2023年4月10日  
    Objectives To examine the national, 6-year trends in in-hospital clinical outcomes of patients with subarachnoid haemorrhage (SAH) who underwent clipping or coiling and the prognostic influence of temporal trends in the Comprehensive Stroke Center (CSC) capabilities on patient outcomes in Japan. Design Retrospective study. Setting Six hundred and thirty-one primary care institutions in Japan. Participants Forty-five thousand and eleven patients with SAH who were urgently hospitalised, identified using the J-ASPECT Diagnosis Procedure Combination database. Primary and secondary outcome measures Annual number of patients with SAH who remained untreated, or who received clipping or coiling, in-hospital mortality and poor functional outcomes (modified Rankin Scale: 3–6) at discharge. Each CSC was assessed using a validated scoring system (CSC score: 1–25 points). Results In the overall cohort, in-hospital mortality decreased (year for trend, OR (95% CI): 0.97 (0.96 to 0.99)), while the proportion of poor functional outcomes remained unchanged (1.00 (0.98 to 1.02)). The proportion of patients who underwent clipping gradually decreased from 46.6% to 38.5%, while that of those who received coiling and those left untreated gradually increased from 16.9% to 22.6% and 35.4% to 38%, respectively. In-hospital mortality of coiled (0.94 (0.89 to 0.98)) and untreated (0.93 (0.90 to 0.96)) patients decreased, whereas that of clipped patients remained stable. CSC score improvement was associated with increased use of coiling (per 1-point increase, 1.14 (1.08 to 1.20)) but not with short-term patient outcomes regardless of treatment modality. Conclusions The 6-year trends indicated lower in-hospital mortality for patients with SAH (attributable to better outcomes), increased use of coiling and multidisciplinary care for untreated patients. Further increasing CSC capabilities may improve overall outcomes, mainly by increasing the use of coiling. Additional studies are necessary to determine the effect of confounders such as aneurysm complexity on outcomes of clipped patients in the modern endovascular era.
  • Ai Kurogi, Daisuke Onozuka, Akihito Hagihara, Kunihiro Nishimura, Akiko Kada, Manabu Hasegawa, Takahiro Higashi, Takanari Kitazono, Tsuyoshi Ohta, Nobuyuki Sakai, Hajime Arai, Susumu Miyamoto, Tetsuya Sakamoto, Koji Iihara, Masayoshi Takigami, Kenji Kamiyama, Kiyohiro Houkin, Shogo Nishi, Sadao Kaneko, Koji Oka, Yusuke Nakagaki, Hiroshi Ooyama, Katsumi Takizawa, Naoki Tokumitsu, Susumu Suzuki, Nozomi Suzuki, Teruo Kimura, Naoto Izumi, Kazumi Nitta, Masafumi Ohtaki, Masanori Isobe, Mikio Nishiya, Mitsunobu Kaijima, Syouji Mabuchi, Kuniaki Ogasawara, Naohiko Kubo, Yukihiko Shimizu, Keiichi Saito, Tatumi Yamanome, Akinori Yabuta, Atsuo Yoshino, Junichi Harashina, Masami Shimoda, Hiroyuki Jimbo, Hideki Murakami, Hiroyuki Masaoka, Hirotoshi Ohtaka, Hiroki Yoshida, Ichiro Suzuki, Michihiro Kohno, Yoshinori Arai, Akira Isoshima, Mitsuhiko Hokari, Kensuke Kawai, Taketoshi Maehara, Hajime Arai, Takakazu Kawamata, Makoto Noguchi, Haruhiko Hoshino, Hirofumi Hiyama, Kensaku Yoshida, Mitsuyuki Fujitsuka, Yasuaki Takeda, Hirohide Karasudani, Shiro Kobayashi, Michio Nakamura, Junichi Ono, Sumio Suda, Hiromu Hadeishi, Kenji Wakui, Hirokazu Tanno, Naoaki Sato, Hideki Sakai, Takashi Matsumoto, Naoki Koketsu, Ichiro Nakahara, Toshinori Hasegawa, Naoto Kuwayama, Nobuhiko Mizutani, Noriyuki Suzaki, Keizo Yasui, Akira Ikeda, Youtarou Takeuchi, Toshihiko Wakabayashi, Hisashi Tanaka, Junpei Yoshimoto, Ogura Koichiro, Toshio Yokoe, Kenichi Murao, Tomonori Yamada, Amami Kato, Akatsuki Wakayama, Hiroharu Kataoka, Kouich Iwatsuki, Yoshikazu Nakajima, Hidefuku Gi, Ryunosuke Uranishi, Yusaku Nakamura, Kazunori Yamanaka, Hiroyuki Matsumoto, Hiroaki Fujiwara, Yoshiyasu Iwai, Masashi Morikawa, Kazuyuki Tane, Kazuo Hashikawa, Shunichi Yoneda, Kohsuke Yamashita, Masahiko Kitano, Kazuhito Nakamura, Katsuhiko Kono, Kenji Ohata, Toshihiko Kuroiwa, Kazusige Maeno, Motohiro Arai, Masaaki Iwase, Kenji Hashimoto, Takashi Tsuruno, Shinichiro Kurokawa, Takeshi Matsuyama, Takamichi Yuguchi, Yoshihumi Teramoto, Takayuki Matsuo, Naoki Kitagawa, Makio Kaminogo, Seisaburo Sakamoto, Yoshiharu Tokunaga, Ei-Ichirou Urasaki, Junichi Kuratsu, Akira Takada, Shu Hasegawa, Toru Nishi, Isao Fuwa, Hiromasa Tsuiki, Hiromasa Tsuiki, Kazunari Koga, Hiroshi Egami, Tadao Kawamura, Makoto Goda, Yu Takeda, Yasuyuki Nagai, Masaki Morisige, Yutaka Yamaguchi, Shiro Miyata, Hideo Takeshima, Kazutaka Yatsushiro, Hajime Ohta, Kazuho Hirahara, Teruaki Kawano, Souichi Obara, Hiroshi Seto, Shunichi Tanaka, Koiti Moroki, Kazunori Arita, Shogo Ishiuchi, Toshimitsu Uchihara, Susumu Mekaru, Tomoaki Nagamine, Jin Momoji, Satoshi Yamamoto, Atusi Kimoto, Tsutomu Kadekaru, Akihiko Saito, Osamu Onodera, Hideaki Takahashi, Hiroyuki Arai, Shigekazu Takeuchi, Hiroki Takano, Osamu Fukuda, Mitsuo Kouno, Igarashi Michitoku, Michiya Kubo, Hiroaki Hondo, Miyamori Tadao, Ryouichi Masuda, Takata Hisashi, Toru Masuoka, Naoki Shirasaki, Hisashi Nitta, Makoto Kimura, Hisato Minamide, Shunsuke Shiraga, Mitsutoshi Nakada, Shuji Sato, Hiroki Toda, Osamu Yamamura, Masanori Kabuto, Jyunya Hayashi, Hiroyuki Kinouchi, Toyoaki Shinohara, Hidehito Koizumi, Mikito Uchida, Syougo Imae, Hiroshi Ozawa, Osamu Nishizaki, Masakazu Suga, Kanehisa Kohno, Kiichiro Zenke, Hiromichi Sadashima, Hikaru Mizobuchi, Satoru Hayashi, Masanori Morimoto, Takeshi Kohno, Tetsuya Ueba, Hiroyuki Nishimura, Norihito Shirakawa, Masahiro Kagawa, Naoki Hayashi, Atsushi Shindo, Kimihiro Yoshino, Tetsuya Masaoka, Kenwakai Otemati Hospital, Ichiro Nakahara, Akira Nakamizo, Yuji Okamoto, Shigenari Kin, Haruki Takahashi, Satoshi Suzuki, Koji Iihara, Katsuyuki Hirakawa, Akira Nakamizo, Akio Ookura, Koichirou Matsukado, Hidenori Yoshida, Hiroshi Nakane, Isao Inoue, Kei Hisada, Tsutomu Hitotsumatsu, Kouichi Kuramoto, Junya Hayashi, Hiromichi Ooishi, Masani Nonaka, Motohiro Morioka, Haruhisa Tsukamoto, Hiroshi Sugimori, Shinichirou Ishihara, Nobuaki Momozaki, Masayuki Miyazono, Akihiro Nemoto, Nobuo Hirota, Hiroaki Tanaka, Hiroshi Tanaka, Atsushi Tsuchiya, Katsumi Sakata, Hidetoshi Murata, Motohiro Nomura, Hitoshi Ozawa, Kotaro Tsumura, Makoto Inaba, Taturou Mori, Tomoaki Terada, Takahisa Mori, Masato Sugitani, Yuichiro Tanaka, Masaru Yamada, Mitsunori Matsumae, Keiichirou Onitsuka, Kosuke Miyahara, Sumio Endou, Atsuhiro Kojima, Shinichi Yagi, Hidekazu Takahashi, Hiroyuki Kaidu, Akira Tsunoda, Kyoichi Nomura, Takamitsu Fujimaki, Hidetoshi Ooigawa, Masahiko Tanaka, Hiroshi Wanihuchi, Hirochiyo Wada, Akio Hyodo, Ken Asakura, Akazi Kazunori, Hideyuki Kurihara, Shigehiro Ohmori, Hiroshi Kusunoki, Satoshi Magarisawa, Shinichi Okabe, Shinji Yamamoto, Hiroko Oyama, Shin Tsuruoka, Mikihiko Takeshita, Akira Matsumura, Kazuya Uemura, Hitoshi Tabata, Keishi Fujita, Masashi Nakatsukasa, Norifumi Shimoeda, Hideo Kunimine, Masayuki Ishihara, Kazuhiro Kikuchi, Nozomu Murai, Warou Taki, Nobukuni Murakami, Minoru Kidooka, Yoshihiro Iwamoto, Hiroshi Tenjin, Kouji Shiga, Nobuhito Mori, Eiji Kohmura, Takeshi Kondoh, Haruo Yamashita, Keigo Matsumoto, Naoya Takeda, Takayuki Sakaki, Hiroji Miyake, Eiichiro Mabuchi, Masayuki Yokota, No, Hideyuki Ohnishi, Masaaki Saiki, Minoru Asahi, Junji Koyama, Yoshio Sakagami, Shinya Noda, Junichi Iida, Tetsuya Morimoto, Hiroyuki Nakase, Hidehiro Hirabayashi, Naoyuki Nakao, Toshikazu Kuwata, Yoshinari Nakamura, Hiroshi Ishiguchi, Teruyuki Habu, Masamichi Kurosaki, Hiroki Ohkuma, Seiko Hasegawa, Hiromu Konno, Atsuhito Takemura, Atsuya Okubo, Hitoshi Saito, Junta Moroi, Hiroaki Shimizu, Masayuki Sasou, Yoichi Watanabe, Kiyoshi Saito, Masahiro Satoh, Zenichiro Watanabe, Takayuki Koizumi, Shoji Mashiyama, Tomoyoshi Oikawa, Sonoda Yukihiko, Rei Kondo, Atsuo Shinoda, Eiichiro Kamatsuka, Keiten So, Toshihiko Kinjo, Kennji Itou, Yohei Kudoh, Kazuhiko Sato, Arai Hiroaki, Hidenori Endo, Hiroshi Karibe, Kou Takahashi, Masayuki Nakajima, Kazuyoshi Watanabe, Kazuhiko Nozaki, Motohiro Takayama, Tarou Komuro, Fumio Suzuki, Hidenori Suzuki, Hiroto Murata, Fumitaka Miya, Seiji Fukazawa, Seiya Takehara, Yoshihiko Watanabe, Teiji Nakayama, Haruhiko Sato, Shinji Amano, Katsuhiro Kuroda, Akira Morooka, Takafumi Wataya, Tetsuya Tanigawara, Toru Iwama, Junki Ito, Shinji Noda, Kazuyuki Kouno, Kazuo Kitazawa, Yoshikazu Kusano, Masanobu Hokama, Hiroki Sato, Sumio Kobayashi, Shinsuke Muraoka, Masaki Miyatake, Kensuke Hayashida, Keiichi Sakai, Fusao Ikawa, Gen Ishida, Takato Kagawa, Youichirou Namba, Hiroyuki Nakashima, Koji Tokunaga, Isao Date, Masaaki Uno, Masaki Chin, Hidemichi Sasayama, Hideyuki Yoshida, Akira Watanabe, Kunihiko Harada, Manabu Urakawa, Yasuhiro Hamada, Michiyasu Suzuki, Takafumi Nishizaki, Katsuhiro Yamashita, Ryuji Nakamura, Masayuki Sumida, Shinichi Wakabayashi, Kaoru Kurisu, Atsushi Tominaga, Masaaki Shibukawa, Kawamoto Yukihiko, Shinji Okita, Kenjirou Hujiwara, Takashi Matsuoka, Osamu Hamasaki, Junichiro Satomi, Masahito Agawa, Hirofumi Oka, Kunikazu Yoshimura, Sei Haga, Katsuyuki Asaoka, Toshitaka Nakamura, Makoto Takeda, Nobuaki Kobayasi, Satoshi Ushikoshi, Nobuhiro Mikuni, Jun Niwa, Rokuya Tanikawa, Akinori Yamamura, Akira Takahashi, Noriaki Watabe, Junkoh Sasaki, Yasunari Otawara, Kazuyuki Miura, Teiji Tominaga, Tatsuya Sasaki, Takayuki Sugawara, Masayuki Ezura, Kenji Yamamoto, Syuichi Ishikawa, Yoshida Masahiro, Sunao Takemura, Masahisa Kawakami, Satoshi Ihara, Yasushi Shibata, Takashi Saegusa, Toshihiko Iuchi, Chiaki Ito, Seiichiro Hoshi, Sumio Isimaru, Osamu Okuda, Kazunari Yoshida, Takekazu Akiyama, Masateru Katayama, Masahiko Kasai, Tomonori Kobayashi, Oikawa Akihiro, Naohisa Miura, Osamu Tao, Takahiro Oota, Atumi Takenobu, Toshihiro Kumabe, Sachio Suzuki, Takashi Kumagai, Keiichi Nishimaki, Kazuhiro Hongo, Yasuyuki Toba, Kuroyanagi Takayuki, Hiroaki Shigeta, Atsushi Sato, Satoshi Kuroda, Cheho Park, Sotaro Higashi, Hirofumi Oyama, Kazuyoshi Hattori, Yoichi Uozumi, Norimoto Nakahara, Mitsuhito Mase, Nobukazu Hashimoto, Toshikazu Ichihashi, Katsunobu Takenaka, Shinichi Shirakami, Yoshinari Okumura, Kazuhiro Yokoyama, Susumu Miyamoto, Yoshinori Akiyama, Kenji Hashimoto, Masaaki Saiki, Kazuo Yamamoto, Naofumi Isono, Tsugumichi Ichioka, Nakazawa Kazutomo, Misao Nishikawa, Tsuyoshi Inoue, Manabu Kinoshita, Shinichi Yoshimura, Minoru Saitoh, Hideo Aihara, Hajimu Miyake, Kazuyuki Kuwayama, Kotaro Ogihara, Shigeki Nishino, Yasuyuki Miyoshi, Tadashi Arisawa, Shigeru Daido, Kimihisa Kinoshita, Keisuke Migita, Keiichi Akatsuka, Hirosuke Fujisawa, Junkoh Yamamoto, Yosimasa Kinosita, Satoshi Inoha, Hitonori Takaba, Tadahisa Shono, Hitoshi Tsugu, Shuji Hayashi, Tatsuya Abe, Susumu Nakashima, Takehisa Tuji, Keizou Yamamoto, Akihiko Kaga, Reizou Kanemaru, Koji Takasaki, Junichi Imamura, Masahiro Noha, Saburo Watanabe, Nobuyuki Sakai, Hiroaki Minami, Tomoyoshi Okumura, Shinjitsu Nishimura, Shinichi Numazawa, Yasunari Niimi, Isao Kitahara, Hidemitu Nakagawa, Kiyoshi Kazekawa, Kouzou Fukuyama, Makoto Ichinose, Koji Matuoka, Yasuhiro Fujimoto, Youichi Hashimoto, Takeshi Matsuoka, Takamitsu Uchizawa, Tomohiko Satou, Makoto Hasebe, Tomoaki Kameda, Hiroaki Sawaura, Takayuki Kubodera, Satoshi Utsuki, Kazuaki Awamori, Chiaki Takahashi, Kazumasa Yamatani, Toshiyuki Tsukada, Ryoichi Hayashi, Masakazu Kitahara, Yukinari Kakizawa, Yasumasa Yamamoto, Takashi Yoshida, Shinji Okumura, Yasunobu Gotou, Takashi Tominaga, Hirotoshi Hamaguchi, Nozomi Mori, Naoki Shinohara, Yasushi Ejima, Mayumi Mori, Hitoshi Miyake, Masaru Idei, Yoshihiro Nishiura, Hiromichi Koga, Kazuya Morimoto, Jae-Hyun Son, Yoshimasa Niiya, Tsuneo Shishido, Mamoru Murakami, Takaaki Yoshida, Masahito Hara, Tatsuya Nakamura, Takuya Kawai, Takashi Inoue, Isao Sasaki, Katsuhiko Hayashi, Ichiro Fujishima, Naoko Fujimura, Seiko Kataoka, Masayuki Yokota
    Scientific Reports 12(1) 2022年12月  
    <title>Abstract</title>To determine whether increasing thrombectomy-capable hospitals with moderate comprehensive stroke center (CSC) capabilities is a valid alternative to centralization of those with high CSC capabilities. This retrospective, nationwide, observational study used data from the J-ASPECT database linked to national emergency medical service (EMS) records, captured during 2013–2016. We compared the influence of mechanical thrombectomy (MT) use, the CSC score, and the total EMS response time on the modified Rankin Scale score at discharge among patients with acute ischemic stroke transported by ambulance, in phases I (2013–2014, 1461 patients) and II (2015–2016, 3259 patients). We used ordinal logistic regression analyses to analyze outcomes. From phase I to II, MTs increased from 2.7 to 5.5%, and full-time endovascular physicians per hospital decreased. The CSC score and EMS response time remained unchanged. In phase I, higher CSC scores were associated with better outcomes (1-point increase, odds ratio [95% confidence interval]: 0.951 [0.915–0.989]) and longer EMS response time was associated with worse outcomes (1-min increase, 1.007 [1.001–1.013]). In phase II, neither influenced the outcomes. During the transitional shortage of thrombectomy-capable hospitals, increasing hospitals with moderate CSC scores may increase nationwide access to MT, improving outcomes.
もっとみる

MISC

 51

講演・口頭発表等

 1

共同研究・競争的資金等の研究課題

 6
もっとみる
一覧へ戻る